OLN324: Why Size May Matter - Takeaways - MDSpire

OLN324: Why Size May Matter

David A. Eichenbaum, MD, FASRS, and Veeral S. Sheth, MD, MBA, discuss phase 1 JADE findings and how OLN324's small-format design may contribute to improved retinal drying in nAMD and diabetic macular edema.

  • By

  • David A. Eichenbaum, MD

  • Veeral S. Sheth, MD, MBA, FACS

  • July 15, 2026

  • 3 min

Share

  • 1

    The phase 1 JADE study compared OLN324 to faricimab in treating age-related macular degeneration and diabetic macular edema.

  • 2

    OLN324 demonstrated better retinal drying and a higher percentage of DME resolution compared to faricimab at week 12.

  • 3

    In AMD, OLN324 showed a gain of 2.2 letters and more significant flattening of pigment epithelial detachments than faricimab.

  • 4

    OLN324's small format (41 kDa) allows for high binding affinity and molarity, distinguishing it from faricimab.

  • 5

    No intraocular inflammation, vascular occlusions, or endophthalmitis were reported in OLN324 patients during the study.

Original Source(s)

OLN324: Why Size May Matter

  • by David A. Eichenbaum, MD, Veeral S. Sheth, MD, MBA, FACS

  • July 15, 2026

Related Content

Ocular Toxoplasmosis Review

Sleep, stress, and pregnancy emerge as potential drivers of ocular toxoplasmosis recurrence in recent retrospective study

  • July 15, 2026

  • 4 min
Efficacy of intradermal acupuncture for ocular surface diseases secondary to refractory peripheral facial palsy: a randomized controlled trial study protocol

Effects of Nd: YAG laser capsulotomy on central macular thickness: a systematic review and meta-analysis